Payment overview · 2025
General Payments
$276.48
13 reported records · 7 companies
Healthcare provider profile · identity verified
Peter Melvin Crane, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MONTPELIER, ID · NPI 1891960233
Verified facts
What the public records show
CMS Open Payments records show Peter Melvin Crane, M.D. received $276.48 in general payments during 2025 across 13 reported records.
Novartis Pharmaceuticals Corporation accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $81.44 | 29.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.51 | 22.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.54 | 17.9% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.96 | 9.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $22.09 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.22 | 7.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.72 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $276.48 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $81.44 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $61.51 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.54 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.54 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| JADA SYSTEM Normalized: jada system |
Device | Organon LLC | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 697 | 168 |
| Omeprazole | Omeprazole | 422 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 415 | 108 |
| Gabapentin | Gabapentin | 325 | 73 |
| Lisinopril | Lisinopril | 320 | 78 |
| Metformin Hcl | Metformin Hcl | 246 | 52 |
| Losartan Potassium | Losartan Potassium | 231 | 67 |
| Furosemide | Furosemide | 223 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 52 |
| Potassium Chloride | Potassium Chloride | 211 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 208 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 41 |
| Trazodone Hcl | Trazodone Hcl | 154 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 34 |
| Simvastatin | Simvastatin | 151 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 36 |
| Tramadol Hcl | Tramadol Hcl | 134 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 24 |
| Metformin Hcl Er | Metformin Hcl | 127 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 123 | 46 |
| Ozempic | Semaglutide | 111 | 20 |
| Sertraline Hcl | Sertraline Hcl | 110 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 24 |
| Montelukast Sodium | Montelukast Sodium | 94 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 84 | 17 |
| Celecoxib | Celecoxib | 79 | 29 |
| Lorazepam | Lorazepam | 77 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 22 |
| Meloxicam | Meloxicam | 75 | 20 |
| Pregabalin | Pregabalin | 75 | 15 |
| Carvedilol | Carvedilol | 73 | 21 |
| Farxiga | Dapagliflozin Propanediol | 71 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 13 |
| Eliquis | Apixaban | 68 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 18 |
| Jardiance | Empagliflozin | 66 | suppressed |
| Myrbetriq | Mirabegron | 63 | suppressed |
| Famotidine | Famotidine | 61 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | suppressed |
| Spironolactone | Spironolactone | 61 | 17 |
| Aripiprazole | Aripiprazole | 59 | 12 |
| Trulicity | Dulaglutide | 58 | suppressed |
| Synthroid | Levothyroxine Sodium | 57 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 20 |
| Ondansetron Odt | Ondansetron | 54 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 53 | suppressed |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 51 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 14 |
| Allopurinol | Allopurinol | 49 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 13 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Cephalexin | Cephalexin | 47 | 21 |
| Ibuprofen | Ibuprofen | 47 | 19 |
| Lamotrigine | Lamotrigine | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 16 |
| Donepezil Hcl | Donepezil Hcl | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 11 |
| Alprazolam | Alprazolam | 43 | suppressed |
| Finasteride | Finasteride | 43 | 12 |
| Bupropion Xl | Bupropion Hcl | 42 | 13 |
| Prednisone | Prednisone | 41 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 28 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Estradiol | Estradiol | 32 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 31 | 28 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 15 |
| Valsartan | Valsartan | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 12 |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Nystatin | Nystatin | 27 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 11 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $276.48 · 13 records | Novartis Pharmaceuticals Corporation | Cologuard Collection Kit, JADA SYSTEM, Kerendia, LEQVIO, Ozempic, QULIPTA, Qelbree, Rybelsus, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error